AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7611577 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (250-500 mg rectally after intubation)
Number of subjects: 50
Study 7611577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% two drops on conjunctiva after intubation)
Number of subjects: 50
Study 7611577 — intervention group
Group type: COMPARATOR
Intervention: Control (rectal paracetamol after operation before extubation)
Number of subjects: 50
Study 2698435 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (RXT) 300 mg/day orally for an average of 9 days
Number of subjects: 48
Study 2698435 — intervention group
Group type: COMPARATOR
Intervention: antibiotic/s (ATB) based on identified microorganisms, mean duration of treatment 12 days
Number of subjects: 48
Study 25567 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 0
Study 25567 — intervention group
Group type: COMPARATOR
Intervention: Dextrorotatory isomer of propranolol
Number of subjects: 0
Study 31675299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-Retaining (CR) implant
Number of subjects: 0
Study 31675299 — intervention group
Group type: COMPARATOR
Intervention: Cruciate-Substituting (PS) implant
Number of subjects: 0
Study 27160848 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy before starting ART cycle
Number of subjects: 220
Study 27160848 — intervention group
Group type: COMPARATOR
Intervention: No office hysteroscopy (control group)
Number of subjects: 220
Study 26667110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=81)
Number of subjects: 160
Study 26667110 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=79)
Number of subjects: 160
Study 26667110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (prepubescent children)
Number of subjects: 160
Study 26667110 — intervention group
Group type: COMPARATOR
Intervention: Control group (prepubescent children)
Number of subjects: 160
Study 23789453 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment including melatonin
Number of subjects: 0
Study 23789453 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy including hepatoprotectors
Number of subjects: 0
Study 21672008 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h structured education with personalized pedometer use
Number of subjects: 98
Study 21672008 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h structured education programme aimed at promoting physical activity
Number of subjects: 98
Study 21672008 — intervention group
Group type: COMPARATOR
Intervention: advice leaflet
Number of subjects: 98
Study 18380936 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with autism and learning disability
Number of subjects: 26
Study 18380936 — intervention group
Group type: COMPARATOR
Intervention: Women with non-autism learning disability (Control group)
Number of subjects: 26
Study 16839346 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBT 986 intravenous infusion
Number of subjects: 0
Study 16839346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12637979 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐Colony Stimulating Factor (G‐CSF) 5 microg/kg daily for 10 days
Number of subjects: 37
Study 12637979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10636257 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily metoprolol tartrate (MT)
Number of subjects: 27
Study 10636257 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily metoprolol succinate (MS)
Number of subjects: 27
Study 9020417 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine (mizolastine)
Number of subjects: 1070
Study 9020417 — intervention group
Group type: COMPARATOR
Intervention: Azelastine nasal spray
Number of subjects: 1070
Study 9020417 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 1070
Study 9020417 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 1070
Study 9020417 — intervention group
Group type: COMPARATOR
Intervention: Azelastine (oral application)
Number of subjects: 1070
Study 1527296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravenous deslanoside (0.002 mg/kg body weight)
Number of subjects: 9
Study 1527296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg of deslanoside (open label assessment)
Number of subjects: 9
Study 1527296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravenous deslanoside
Number of subjects: 9
Study 1527296 — intervention group
Group type: EXPERIMENTAL
Intervention: Deslanoside (both doses)
Number of subjects: 9
Study 1527296 — intervention group
Group type: EXPERIMENTAL
Intervention: Deslanoside
Number of subjects: 9
Study 3880585 — intervention group
Group type: EXPERIMENTAL
Intervention: Desamino-D-arginine vasopressin
Number of subjects: 37
Study 3880585 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 37
Study 29352518 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion (CWI) of 0.2% ropivacaine at 10 ml/h for 48 hours
Number of subjects: 95
Study 29352518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVL) of 1.5% lidocaine at 4 ml/h for 48 hours
Number of subjects: 95
Study 29352518 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 28341613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen with antioxidants (Spirulina and dimethylmethoxy chromanol)
Number of subjects: 44
Study 28341613 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen without antioxidants (control)
Number of subjects: 44
Study 26646026 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-adjustable workstations and supporting techniques
Number of subjects: 238
Study 26646026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 238
Study 24251361 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of warfarin
Number of subjects: 1015
Study 24251361 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided dosing of warfarin
Number of subjects: 1015
Study 20868741 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 17
Study 20868741 — intervention group
Group type: COMPARATOR
Intervention: methadone
Number of subjects: 17
Study 18441707 — intervention group
Group type: EXPERIMENTAL
Intervention: magnerot
Number of subjects: 144
Study 18441707 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 144
Study 18441707 — intervention group
Group type: COMPARATOR
Intervention: placebo (control group)
Number of subjects: 144
Study 16778691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical epidural steroid injections at C6-C7
Number of subjects: 0
Study 16778691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical epidural steroid injections at C7-T1
Number of subjects: 0
Study 16778691 — intervention group
Group type: COMPARATOR
Intervention: Cervical epidural steroid injections at both levels
Number of subjects: 0
Study 12680863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Number of subjects: 16
Study 12680863 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge (diluent)
Number of subjects: 16
Study 11434595 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily, amoxycillin 750 mg three times a day, metronidazole 500 mg three times a day (OAM)
Number of subjects: 456
Study 11434595 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily, amoxycillin 750 mg three times a day, metronidazole 500 mg three times a day (RAM)
Number of subjects: 456
Study 11434595 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM
Number of subjects: 456
Study 11434595 — intervention group
Group type: COMPARATOR
Intervention: RAM
Number of subjects: 456
Study 9629968 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely selected movements (free mode)
Number of subjects: 31
Study 9629968 — intervention group
Group type: COMPARATOR
Intervention: Fixed movements (fixed mode)
Number of subjects: 31
Study 10184179 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminology clarification in physician orders
Number of subjects: 0
Study 3286439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exifone 600 mg/d
Number of subjects: 0
Study 3286439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exifone 1200 mg/d
Number of subjects: 0
Study 3286439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31859346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) with and without methotrexate (MTX)
Number of subjects: 317
Study 31859346 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 317
Study 29561282 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative 5-fluorouracil-based adjuvant therapies
Number of subjects: 3714
Study 27911654 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp social groups
Number of subjects: 82
Study 27911654 — intervention group
Group type: COMPARATOR
Intervention: Facebook social groups
Number of subjects: 82
Study 25041467 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid plus antiviral agents (S + A group, n = 569)
Number of subjects: 1342
Study 25041467 — intervention group
Group type: COMPARATOR
Intervention: Steroid alone (S group, n = 773)
Number of subjects: 1342
Study 25041467 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid plus antiviral agents (S + A group)
Number of subjects: 1342
Study 25041467 — intervention group
Group type: COMPARATOR
Intervention: Steroid alone (S group)
Number of subjects: 1342
Study 22260244 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 63
Study 22260244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21599732 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal epidural analgesia
Number of subjects: 1054
Study 21599732 — intervention group
Group type: COMPARATOR
Intervention: Low-dose infusion
Number of subjects: 1054
Study 21599732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epidural
Number of subjects: 1054
Study 18283138 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL of 7.5% hypertonic saline and 6% dextran 70 (HSD)
Number of subjects: 209
Study 18283138 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution (LRS)
Number of subjects: 209
Study 17065882 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT cuff manipulation (cuff maintained at 20 mmHg or less, deflated for 5 seconds and then reinflated)
Number of subjects: 100
Study 17065882 — intervention group
Group type: COMPARATOR
Intervention: No manipulation of ETT cuff after intubation (control group)
Number of subjects: 100
Study 17065882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 12848266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 0
Study 10502592 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization followed by continued medical therapy
Number of subjects: 275
Study 10502592 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 275
Study 10502592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 275
Study 8942248 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral 40 mg/kg
Number of subjects: 191
Study 8942248 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine 3 mg/kg
Number of subjects: 191
Study 8942248 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 191
Study 8942248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 1781032 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day educational intervention against smoking
Number of subjects: 17446
Study 1781032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17446
Study 7138721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position for 2.5 min or more during and after injection of 3 ml of 0.5% isobaric bupivacaine‐HCl
Number of subjects: 40
Study 7138721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 40
Study 7138721 — intervention group
Group type: COMPARATOR
Intervention: Lateral horizontal position (Control)
Number of subjects: 40
Study 7138721 — intervention group
Group type: EXPERIMENTAL
Intervention: C.S.F. indices (pressure, protein, chloride ion concentration, pH, specific gravity)
Number of subjects: 40
Study 30718952 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg once daily for 16 weeks
Number of subjects: 0
Study 30718952 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 0
Study 30718952 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC)
Number of subjects: 0
Study 28244117 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM-ON)
Number of subjects: 595
Study 28244117 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Follow-up (RM-OFF)
Number of subjects: 595
Study 26199168 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum treatment
Number of subjects: 0
Study 24172265 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circulation (MECC)
Number of subjects: 61
Study 24172265 — intervention group
Group type: COMPARATOR
Intervention: Standard extracorporeal circulation (SECC)
Number of subjects: 61
Study 24172265 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (OPCABG)
Number of subjects: 61
Study 21382866 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported exercise programme (12 weeks)
Number of subjects: 99
Study 21382866 — intervention group
Group type: COMPARATOR
Intervention: Standard care (12 weeks)
Number of subjects: 99
Study 18808404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 20
Study 18808404 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care immunosuppression (Thymoglobulin and/or pulse steroids)
Number of subjects: 20
Study 17134488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravenous furosemide 40 mg (Group 1)
Number of subjects: 18
Study 17134488 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous furosemide 120 mg (Group 2)
Number of subjects: 18
Study 17134488 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 12945021 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amitriptyline 50 mmol/L
Number of subjects: 14
Study 12945021 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amitriptyline 100 mmol/L
Number of subjects: 14
Study 12945021 — intervention group
Group type: COMPARATOR
Intervention: Topical amitriptyline 10 mmol/L
Number of subjects: 14
Study 12945021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12945021 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amitriptyline
Number of subjects: 14
Study 11004739 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery
Number of subjects: 72
Study 11004739 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative imagery
Number of subjects: 72
Study 11004739 — intervention group
Group type: COMPARATOR
Intervention: No imagery
Number of subjects: 72
Study 8842889 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Kader method
Number of subjects: 74
Study 8842889 — intervention group
Group type: COMPARATOR
Intervention: Didactic methods
Number of subjects: 74
Study 2064495 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 2000 mg
Number of subjects: 201
Study 2064495 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 1500 mg
Number of subjects: 201
Study 2064495 — intervention group
Group type: COMPARATOR
Intervention: Placebo and diet treatment
Number of subjects: 201
Study 6853992 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction biopsy technique
Number of subjects: 18
Study 6853992 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic biopsy technique
Number of subjects: 18
Study 6853992 — intervention group
Group type: COMPARATOR
Intervention: Acid reflux test
Number of subjects: 18
Study 6853992 — intervention group
Group type: COMPARATOR
Intervention: Histologic criteria for gastroesophageal reflux
Number of subjects: 18
Study 3957518 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive work (eta)
Number of subjects: 61
Study 3957518 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative work (eta‐)
Number of subjects: 61
Study 3957518 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated electrical activity (IEMG)
Number of subjects: 61
Study 30792988 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg efavirenz
Number of subjects: 132
Study 30792988 — intervention group
Group type: COMPARATOR
Intervention: 600 mg efavirenz
Number of subjects: 132
Study 27357200 — intervention group
Group type: EXPERIMENTAL
Intervention: Young mothers aged ≤16 years
Number of subjects: 4749
Study 27357200 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparous women aged ≤16 years
Number of subjects: 4749
Study 27357200 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 4749
Study 24827136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C with maintenance chemotherapy (MMC/Maint)
Number of subjects: 940
Study 24827136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with maintenance chemotherapy (CisP/Maint)
Number of subjects: 940
Study 24827136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C without maintenance chemotherapy (MMC/No-maint)
Number of subjects: 940
Study 24827136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin without maintenance chemotherapy (CisP/No-maint)
Number of subjects: 940
Study 24827136 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CisP)
Number of subjects: 940
Study 22082108 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system usage intention based on the Technology Acceptance Model (TAM)
Number of subjects: 234
Study 22082108 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TAM including Facilitators
Number of subjects: 234
Study 20480054 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice (1% zinc citrate)
Number of subjects: 35
Study 20480054 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 35
Study 18711110 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 68
Study 18711110 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 68
Study 15877562 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training (biofeedback-assisted pelvic floor muscle exercises)
Number of subjects: 197
Study 15877562 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (oxybutynin IR titrated from 2.5 mg per day to 5.0 mg three times a day)
Number of subjects: 197
Study 15877562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 12508333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0
Study 12508333 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 0
Study 12508333 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric content (high vs low)
Number of subjects: 0
Study 12508333 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile status (AP vs NP)
Number of subjects: 0
Study 10499828 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2 ethylenediaminetetraacetic acid (edta) solution
Number of subjects: 10
Study 10499828 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 10
Study 7489470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of midazolam 0.4 mg.kg‐1 + ketamine 4 mg.kg‐1
Number of subjects: 60
Study 7489470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg.kg‐1
Number of subjects: 60
Study 7489470 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 60
Study 1659494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg QD)
Number of subjects: 68
Study 1659494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (120 to 480 mg QD)
Number of subjects: 68
Study 6220476 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 60
Study 6220476 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study 31968049 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for predicting pulmonary to systemic flow ratio from chest radiographs
Number of subjects: 657
Study 31968049 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 657
Study 30912737 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Up Milk - Lite (GUMLi)
Number of subjects: 160
Study 30912737 — intervention group
Group type: COMPARATOR
Intervention: Cows' milk (control)
Number of subjects: 160
Study 29503075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone
Number of subjects: 180
Study 29503075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime
Number of subjects: 180
Study 29503075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin
Number of subjects: 180
Study 29503075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin
Number of subjects: 180
Study 29503075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 180
Study 29503075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 180
Study 27034958 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation at 3 g/d for 8 weeks
Number of subjects: 10
Study 27034958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25144625 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of 50-60 min of aerobic exercise
Number of subjects: 301
Study 22920807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative exergame (n = 14)
Number of subjects: 31
Study 22920807 — intervention group
Group type: COMPARATOR
Intervention: Competitive exergame (n = 17)
Number of subjects: 31